Event description:

The immune system weakens with age and this concept is named “immunosenescence”. Immunosenescence contributes to a reduced ability to respond to natural infections but also to develop optimal immunity following administration of some vaccines. Indeed, while vaccines against tetanus, diphtheria, pertussis and hepatitis have demonstrated immunogenicity and acceptable safety profiles in older adults, some other vaccines have only limited efficacy.

As the population of countries ages, an increasing proportion of adults are therefore at increased risk of infectious diseases including those that are preventable by vaccination. Although a number of vaccines are currently recommended for older adults, vaccination coverage in this particular group remains low.

Fortunately, novel technology has facilitated the development of new and/or improved vaccines for adults that could significantly contribute to the implementation of healthy aging strategies.

A large panel of renowned immunologists, microbiologists, vaccinologists, public health experts, infectious diseases specialists, and geriatricians will share their clinical experience with vaccine-preventable disease in older patients and explain the mechanisms of immunosenescence and the impact of immune aging on vaccination, but also provide the latest developments in vaccine science that may improve the efficacy of vaccines in this age group.

Registration fee: 80.00 Singapore dollars
For online registration, please visit website: www.isirv.org
For inquiries, email: admin@isirv-imrp.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Module &amp; summary of content</th>
<th>Speaker(s) &amp; affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 13:20</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>
| 13:20 - 13:30 | Welcome and introduction    | Gavin SMITH  
Professor, Programme in Emerging Infectious Disease, Duke-NUS Medical School, Singapore |
| 13:30 - 14:10 | What is immunosenescence?   | OOI Eng Eong  
Professor & Deputy Director, Programme in Emerging Infectious Disease, Duke-NUS Medical School, Singapore |
| 13:30 - 14:10 | Biological age: an immunologist perspective (definition of immunosenescence, chronological age vs biological age) | Lisa F.P. NG  
Sr. Principal Investigator, Laboratory of Microbial Immunity, A*STAR, Singapore |
| 13:30 - 14:10 | Changes in the immune system associated with age (effects of age on the various compartments of the immune system) | Linlin WIJAYA  
Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore |
| 14:10 - 15:25 | Impact of immunosenescence on vaccination | Limin WIJAYA  
Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore |
| 14:10 - 15:25 | Why vaccinate older adults (vaccines recommended in older age groups, rationale of vaccines usually recommended) | Limin WIJAYA  
Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore |
| 14:10 - 15:25 | Immune response to vaccination in older adults (normal immune response to vaccination vs reduced immune response to vaccines in elderly) | Limin WIJAYA  
Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore |
| 14:10 - 15:25 | Immunosenescence and the experience with Hepatitis A and Hepatitis B vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults) | Woo-Yun SOHN  
South East Asia Cluster Medical Lead, GSK Vaccines |
| 14:10 - 15:25 | Immunosenescence and experience with influenza vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults) | Philippe BUCHY  
Director, Scientific Affairs & Public Health, GSK Vaccines |
| 14:10 - 15:25 | Immunosenescence and response to inactivated and live-attenuated zoster vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults) | Michael NISSEN  
Director, Scientific Affairs & Public Health, GSK Vaccines |
| 14:10 - 15:25 | Q&A                         | All speakers                                                                            |
| 14:30 - 15:25 | Impact of immunosenescence on vaccination | Limin WIJAYA  
Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore |
| 14:30 - 15:25 | Why vaccinate older adults (vaccines recommended in older age groups, rationale of vaccines usually recommended) | Limin WIJAYA  
Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore |
| 14:30 - 15:25 | Immune response to vaccination in older adults (normal immune response to vaccination vs reduced immune response to vaccines in elderly) | Limin WIJAYA  
Sr. Consultant, Dept. Infectious Diseases, SGH, Singapore |
| 14:30 - 15:25 | Immunosenescence and the experience with Hepatitis A and Hepatitis B vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults) | Woo-Yun SOHN  
South East Asia Cluster Medical Lead, GSK Vaccines |
| 14:30 - 15:25 | Immunosenescence and experience with influenza vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults) | Philippe BUCHY  
Director, Scientific Affairs & Public Health, GSK Vaccines |
| 14:30 - 15:25 | Immunosenescence and response to inactivated and live-attenuated zoster vaccines (disease burden, clinical particularities, immunogenicity and efficacy of vaccines in older adults) | Michael NISSEN  
Director, Scientific Affairs & Public Health, GSK Vaccines |
| 14:30 - 15:25 | Q&A                         | All speakers                                                                            |
| 15:25 - 15:50 | Tea break                   |                                                                                       |
| 15:50 - 16:45 | How to improve the efficacy of vaccination in older adults? | Sanjoy DATTA  
Vice President, Clinical R&D & Medical Affairs, GSK Vaccines |
| 15:50 - 16:45 | Contribution of herd immunity to protection of older adults (principles, example of influenza vaccination of young children to provide herd immunity for older adults) | Sanjoy DATTA  
Vice President, Clinical R&D & Medical Affairs, GSK Vaccines |
| 15:50 - 16:45 | Higher vaccine doses (influenza, zoster) | Philippe BUCHY  
Director, Scientific Affairs & Public Health, GSK Vaccines |
| 15:50 - 16:45 | Alternative delivery routes | Béatrice LAUPÈZE  
Sr. Mgr., Global Medical Affairs, GSK Vaccines |
| 15:50 - 16:45 | Adjuvants (mechanisms of action, aluminium, MF59, GSK adjuvant systems, etc.) | Béatrice LAUPÈZE  
Sr. Mgr., Global Medical Affairs, GSK Vaccines |
| 15:50 - 16:45 | Q&A                         | All speakers                                                                            |
| 16:45 - 18:10| Case studies – Clinical expert's opinion (list of indicative topics that could be covered by clinicians) | Doo-Ryeon CHUNG  
Professor & Chief, Division of Infectious Diseases, Sungkyunkwan University School of Medicine, Samsung Medical Centre, South Korea |
| 16:45 - 18:10| Challenges in preventing pneumococcal disease in older adults | Doo-Ryeon CHUNG  
Professor & Chief, Division of Infectious Diseases, Sungkyunkwan University School of Medicine, Samsung Medical Centre, South Korea |
| 16:45 - 18:10| Shingles – clinical case report | LEO Yee Sin  
Professor & Director of Institute of Infectious Disease and Epidemiology, TTSH, Singapore  
Clinical Director of Communicable Disease Centre, TTSH, Singapore |
| 16:45 - 18:10| Tetanus, diphtheria and pertussis in older adults: what are the risks? | LEONG Hoe Nam  
Infectious Disease Physician, Mt. Elizabeth Novena Hospital, Singapore |
| 16:45 - 18:10| Influenza – Impact of influenza disease on older adults with and without particular underlying diseases | Reshma A MERCHANT  
Assoc. Prof. & Head of Division of Geriatric Medicine, NUS, Singapore |
| 16:45 - 18:10| How to improve vaccination uptake in older adults? A clinician's perspective | Hanley HO Jian An  
Consultant of Dept. of Clinical Epidemiology, TTSH, Singapore |
| 16:45 - 18:10| Q&A                         | All speakers                                                                            |
| 18:10 - 18:15| Closure                     | Gavin SMITH  
Professor, Programme in Emerging Infectious Disease, Duke-NUS Medical School, Singapore |